Why Beyondspring Inc (NASDAQ: BYSI) stock is falling

Free $100 Forex No-Deposit Bonus

Beyondspring Inc (NASDAQ: BYSI) stock fell 3.34% on September 18th, 2019 (Source: Google finance) and continued its weak momentum on September 20th, 2019 (as of 11:32 am GMT-4 ; Source: Google finance) after the company in the second quarter of FY 19 has reported the net loss attributable to the Company of $7.4 million compared to $12.2 million for the quarter ended June 30, 2018. As of June 30, 2019, the Company had the cash balance of $0.7 million.

R&D expenses in the second quarter of 2019 were $5.2 million compared to $11 million in the same period last year. The decrease of $5.8 million was largely attributable to a $3.9 million decrease in expenses incurred by CROs and other service fees related to clinical trials, a $1.1 million decrease in manufacturing expenses and a $0.8 million decrease in non-cash share-based compensation. G&A expenses were $2.1 million in the second quarter of 2019 compared to $1.4 million for the same quarter of 2018. The increase was mainly due to non-cash share-based compensation.

On the other hand, On July 19, 2019, BYSI had closed a public offering, which was led by Decheng Capital, of 2,058,825 ordinary shares and was offered at a public offer price of $17 per share. The company received the gross proceeds from this offer of $35 million. This is before deducting underwriting discounts and commissions and other offering expenses. The Company has planned to use the funds raised of this offering to underpin continued clinical and pre-clinical development and for general corporate purposes.

In June and July 2019, BYSI’s partially owned Chinese subsidiary, Dalian Wanchunbulin Pharmaceuticals Ltd. had signed the definitive agreements for selling its equity interests to certain investors led by Efung Capital. As per this Equity Purchase Agreements, Wanchunbulin planned to sell 4.76% of the equity of Wanchunbulin for total cash consideration of RMB 100 million, or about $14.5 million, before deducting offering expenses, to finance clinical and pre-clinical development and for general corporate purposes. To date, the Company had received RMB 70 million, or about $10.1 million, from this equity financing.

In May 2019, BYSI had signedan Open Market Sale AgreementSM with Jefferies LLC for selling common shares of the Company. This is for aggregate gross amount of up to $30.0 million, from time to time, through an at-the-market (“ATM”) facility. However, in July 2019, this facility was suspended in expectation of the public offering completed on July 19, 2019. As at the ATM’s suspension date, the Company had got total of $13 million on 620,753 common shares already sold through this facility.

Copyright © 2019. All Rights Reserved. FXDailyReport.Com
Risk Warning: Trading CFDs is a high risk activity and you may lose more than your initial deposit. You should never invest money that you cannot afford to lose. FXDailyReport.com will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets.